Amgen Inc.
- AMGN
- NASDAQ
- Drug manufacturers
- Biotech Drugs
- Oncology/Inflammation Therapeutics
$432.49
Today −0.35%Quote Oct 16, 2026, 08:00 PM UTC
+13.88%over the last month
Max drawdown −5.0%From 1-month high −0.4%3 months +18.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$233.82B
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$401.16
−7.2% from here
Floor
$431.32
0.3% below price
Where the price sits
41 analysts
Analyst range, low to high
$230.00$500.00
- Price $432.49
- Resistance $443.12–$447.58
- Consensus $401.16
The price is just above its floor and right under resistance. Analysts' average target sits about 7% lower. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AMGNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $10.05B
- Other products$1.70B16.9%
- Repatha$953.0M9.5%
- Prolia$759.0M7.5%
- EVENITY$714.0M7.1%
- ENBREL$580.0M5.8%
- TEPEZZA$576.0M5.7%
- Other revenues$517.0M5.1%
- Otezla$491.0M4.9%
- TEZSPIRE$486.0M4.8%
- BLINCYTO$472.0M4.7%
- Nplate$430.0M4.3%
- KRYSTEXXA$400.0M4.0%
- Other$1.98B19.7%
Industry
Drug manufacturers
Employees
31,500